Evaluation of treatment results and prognostic factors in early-stage cervical carcinoma patients treated with postoperative radiotherapy or radiochemotherapy

Purpose: To investigate the clinical features, prognostic factors, and treatment outcome in early-stage cervical carcinoma patients treated with postoperative radiotherapy (RT)/radiochemotherapy (RCT). Methods: The records of 256 Stage IB and 11 cervical cancer patients treated with postoperative RT/RCT from 1992-2007 were retrospectively reviewed. Median age of the patients was 47 (range: 25-78). Two hundred one (78.6%) patients had squamous cell carcinoma and 29(11.3%) had adenocarcinoma. One hundred and eighty-seven (73.0%) had FIGO Stage IB and 69 (27%) had Stage II disease. Concomitant cisplatin-based chemotherapy was administered to 47 (18.4%) patients. Metastatic lymph node ratio (MLNR), defined as number of metastatic lymph nodes divided by the number of dissected lymph nodes, was 0 in 142 (55.5%) patients, from 1% to 10% in 27 (10.5%) and > 10% in 31(12.1%) patients. Results: Median follow-up duration was 60.5 months (range: 6-202 months). Five-year locoregional control (LRC), disease-free survival (DFS), disease specific survival (DSS) and overall survival (OS) rates were 90.8%, 83.4%, 91.2%, and 85%, respectively. In multivariate analysis; bulky tumor (> 4 cm) was shown as an important prognostic factor for LRC, DFS and DSS. Pretreatment hemoglobin level (< 10 g/dl) was associated with lower OS rate. Endometrial involvement was associated with lower LRC and DFS. Treatment break > 14 days showed significance for DFS and DSS. MLNR was found as a valuable prognostic factor for all endpoints (LRC, DFS, DSS and OS). The rate of grade 3-4 late toxicity was 3.6% and 2%, respectively. Conclusion: Postoperative RT/RCT is an effective treatment modality for early-stage cervical cancer patients with unfavorable features and provides satisfactory local control and survival rates with low morbidity.

Cervical cancer; Radiotherapy; Radiochemotherapy; Prognostic factors; Metastatic lymph node ratio; Side-effects

[1] Landoni F., Maneo A., Colombo A., Plaga F., Milani R., Perego P. et al.: “Randomised study of radical surgery versus radiotherapy for Stage Ib-IIa cervical cancer”. Lancet, 1997, 350, 535.

[2] Halperin E.C., Perez C.A., Brady L.W.: “Perez and Brady’s Principles and Practice of Radiation Oncology”. 5th ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins, 2008.

[3] Rotman M., Sedlis A., Piedmonte M.R., Bundy B., Lentz S.S., Muderspach L.I., Zaino R.J.: “A phase III randomized trial of postoperative pelvic irradiation in Stage IB cervical carcinoma with poor prognostic features: follow-up of a gynecologic oncology group study”. Int. J. Radiat. Oncol. Biol. Phys., 2006, 65, 169.

[4] Curtin J.P., Hoskins W.J., Venkatraman E.S., Almadrones L., Podratz K.C., Long H. et al.: “Adjuvant chemotherapy versus chemotherapy plus pelvic irradiation for high-risk cervical cancer patients after radical hysterectomy and pelvic lymphadenectomy (RH-PLND): a randomized phase III trial”. Gynecol. Oncol., 1996, 61, 3.

[5] Grigsby P.W.: “Postoperative irradiation in cervical cancer: prognostic factors and outcome”. Radiat. Med., 2004, 22, 106.

[6] Beesley V., Janda M., Eakin E., Obermair A., Battistutta D.: “Lymphedema after gynecological cancer treatment : prevalence, correlates, and supportive care needs”. Cancer, 2007, 109, 2607.

[7] Montz F.J., Holschneider C.H., Solh S., Schuricht L.C., Monk B.J.: “Small bowel obstruction following radical hysterectomy: risk factors, incidence, and operative findings”. Gynecol. Oncol., 1994, 53, 114.

[8] Cox J.D., Stetz J., Pajak T.F.: “Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)”. Int. J. Radiat. Oncol. Biol. Phys., 1995, 31, 1341.

[9] Atahan I.L., Yildiz F., Ozyar E., Pehlivan B., Genc M., Kose M.F. et al.: “Radiotherapy in the adjuvant setting of cervical carcinoma: treatment, results, and prognostic factors”. Int. J. Gynecol. Cancer, 2007, 17, 813.

[10] Tsai C.S., Lai C.H., Wang C.C., Chang J.T., Chang T.C., Tseng C.J., Hong J.H.: “The prognostic factors for patients with early cervical cancer treated by radical hysterectomy and postoperative radiotherapy”. Gynecol. Oncol., 1999, 75, 328.

[11] Ho C.M., Chien T.Y., Huang S.H., Wu C.J., Shih B.Y., Chang S.C. et al.: “Multivariate analysis of the prognostic factors and outcomes in early cervical cancer patients undergoing radical hysterectomy”. Gynecol. Oncol., 2004, 93, 458.

[12] Lai C.H., Hong J.H., Hsueh S., Ng K.K., Chang T.C., Tseng C.J. et al.: “Preoperative prognostic variables and the impact of postoperative adjuvant therapy on the outcomes of Stage IB or II cervical carcinoma patients with or without pelvic lymph node metastases: an analysis of 891 cases”. Cancer, 1999, 85, 1537.

[13] Aoki Y., Sasaki M., Watanabe M., Sato T., Tsuneki I., Aida H., Tanaka K.: “High-risk group in node-positive patients with Stage IB, IIA, and IIB cervical carcinoma after radical hysterectomy and postoperative pelvic irradiation”. Gynecol. Oncol., 2000, 77, 305.

[14] Peters W.A. 3rd, Liu P.Y., Barrett R.J. 2nd, Stock R.J., Monk B.J., Berek J.S. et al.: “Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix”. J. Clin. Oncol., 2000, 18, 1606.

[15] Kodama J., Seki N., Masahiro S., Kusumoto T., Nakamura K., Hongo A., Hiramatsu Y.: “Prognostic factors in Stage IB-IIB cervical adenocarcinoma patients treated with radical hysterectomy and pelvic lymphadenectomy”. J. Surg. Oncol., 101, 413.

[16] Piura B., Rabinovich A., Friger M.: “Surgical pathologic factors in patients with early-stage cervical carcinoma treated with radical hysterectomy and pelvic lymph node dissection: association with administration of adjuvant radiotherapy and effect on survival”. Eur. J. Gynaecol. Oncol., 2006, 27, 573.

[17] Sartori E., Tisi G., Chiudinelli F., La Face B., Franzini R., Pecorelli S.: “Early stage cervical cancer: adjuvant treatment in negative lymph node cases”. Gynecol. Oncol., 2007, 107, S170.

[18] Liu M.T., Hsu J.C., Liu W.S., Wang A.Y., Huang W.T., Chang T.H., Pi C.P., Huang C.Y. et al.: “Prognostic factors affecting the outcome of early cervical cancer treated with radical hysterectomy and post-operative adjuvant therapy”. Eur. J. Cancer Care (Engl.), 2008, 17, 174.

[19] Qiu H.B., Zhang L.Y., Li Y.F., Zhou Z.W., Keshari R.P., Xu R.H.: “Ratio of metastatic to resected lymph nodes enhances to predict survival in patients with Stage III colorectal cancer”. Ann. Surg. Oncol., 2011, 18, 1568.

[20] Showalter T.N., Winter K.A., Berger A.C., Regine W.F., Abrams R.A., Safran H. et al.: “The influence of total nodes examined, number of positive nodes, and lymph node ratio on survival after surgical resection and adjuvant chemoradiation for pancreatic cancer: a secondary analysis of RTOG 9704”. Int. J. Radiat. Oncol. Biol. Phys., 2011, 81, 1328. Epub 2010 Oct. 8.

[21] Polterauer S., Hefler L., Seebacher V., Rahhal J., Tempfer C., Horvat R. et al.: “The impact of lymph node density on survival of cervical cancer patients”. Br. J. Cancer, 103, 613.

[22] Benedetti Panici P., Basile S., Angioli R.: “Pelvic and aortic lymphadenectomy in cervical cancer: the standardization of surgical procedure and its clinical impact”. Gynecol. Oncol., 2009, 113, 284.

[23] Kesic V.: “Management of cervical cancer”. Eur. J. Surg. Oncol., 2006, 32, 832.

[24] Pieterse Q.D., Kenter G.G., Gaarenstroom K.N., Peters A.A., Willems S.M., Fleuren G.J., Trimbos J.B.: “The number of pelvic lymph nodes in the quality control and prognosis of radical hysterectomy for the treatment of cervical cancer”. Eur. J. Surg. Oncol., 2007, 33, 216.

[25] Mayr N.A., Wang J.Z., Zhang D., Montebello J.F., Grecula J.C., Lo S.S. et al.: “Synergistic effects of hemoglobin and tumor perfusion on tumor control and survival in cervical cancer”. Int. J. Radiat. Oncol. Biol. Phys., 2009, 74, 1513.